Stevanato Group S.p.A.
HealthcareNYSE:STVN · New York Stock Exchange
-$0.20 today
Vol 0.49M · Avg 0.51M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$1.2B of revenue converted into $140.9M of net income for the selected period. Gross margin is 28.9% and net margin is 11.6%, showing how much revenue survives after costs and taxes. EPS is $0.51, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1B +3.2% | $1.1B +1.7% | $1.1B +10.3% | $983.7M +16.6% | $843.9M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $809.2M +0.9% | $801.7M +7.5% | $745.5M +12.3% | $663.9M +14.8% | $578.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $330.3M +9.3% | $302.3M -11.1% | $339.9M +6.3% | $319.8M +20.5% | $265.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 29.0% +1.6pp | 27.4% -3.9pp | 31.3% -1.2pp | 32.5% +1.1pp | 31.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $24.4M -23.0% | $31.7M -11.2% | $35.7M +3.7% | $34.4M +16.1% | $29.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $122.9M +3.6% | $118.6M +4.1% | $113.9M +1.9% | $111.8M +34.8% | $83.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $147.2M +4.3% | $141.2M +1.4% | $139.2M +9.3% | $127.4M +23.4% | $103.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $85.1M +5.5% | $80.7M +2.8% | $78.5M +21.1% | $64.8M +15.0% | $56.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | $288.5M +16.4% | $247.8M -9.0% | $272.3M +6.2% | $256.4M +13.0% | $226.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 25.3% +2.9pp | 22.4% -2.6pp | 25.1% -1.0pp | 26.1% -0.8pp | 26.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | $183.1M +13.6% | $161.1M -19.7% | $200.7M +4.3% | $192.4M +18.6% | $162.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 16.1% +1.5pp | 14.6% -3.9pp | 18.5% -1.1pp | 19.6% +0.3pp | 19.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $12.5M +624.7% | $1.7M +117.6% | $792.0K +22.2% | $648.0K +18.2% | $548.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $21.8M +217.7% | $6.9M +59.1% | $4.3M +9.6% | $3.9M -19.2% | $4.9M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.4M -68.7% | -$854.0K +92.4% | -$11.2M -133.1% | -$4.8M -238.9% | $3.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $181.6M +13.3% | $160.3M -15.4% | $189.6M +1.0% | $187.6M +13.3% | $165.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 15.9% +1.4pp | 14.5% -2.9pp | 17.5% -1.6pp | 19.1% -0.6pp | 19.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $47.4M +11.4% | $42.5M -3.1% | $43.9M -1.7% | $44.6M +42.1% | $31.4M | $1.3B | -$1.6B | $745.2M |
| Net Income | $134.3M +14.0% | $117.8M -19.1% | $145.6M +1.9% | $142.8M +6.3% | $134.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | 11.8% +1.1pp | 10.7% -2.7pp | 13.4% -1.1pp | 14.5% -1.4pp | 15.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +14.0% | $0 -21.8% | $1 +3.8% | $1 +0.0% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +14.0% | $0 -21.8% | $1 +3.8% | $1 +0.0% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $273.0M +0.0% | $272.9M +3.0% | $265.0M +0.1% | $264.7M +0.0% | $264.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $273.0M +0.0% | $272.9M +3.0% | $265.0M +0.1% | $264.7M +0.0% | $264.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Axsome Therapeutics, Inc.
NASDAQ:AXSM
$13.13B
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
$12.26B
Masimo Corporation
NASDAQ:MASI
$9.42B
Nuvalent, Inc.
NASDAQ:NUVL
$9.07B
AptarGroup, Inc.
NYSE:ATR
$7.51B
Avantor, Inc.
NYSE:AVTR
$6.41B
Teleflex Incorporated
NYSE:TFX
$5.78B
Chemed Corporation
NYSE:CHE
$5.56B
Bausch + Lomb Corporation
NYSE:BLCO
$5.38B
Merit Medical Systems, Inc.
NASDAQ:MMSI
$3.97B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does STVN generate?
Stevanato Group S.p.A. (STVN) reported $1.14B of revenue in fiscal 2025.
Is STVN profitable?
Stevanato Group S.p.A. (STVN) reported $134.28M of net income, with a net margin of 11.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.